We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.
In Vivo is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183
Fondazione licenses rare genetic disease agents to Glaxo
12 Apr 2018
Executive Summary
Fondazione Telethon (Italian nonprofit organization that supports genetic disease research) and the Fondazione San Raffaele del Monte Tabor (scientific institute) have granted GlaxoSmithKline PLC exclusive worldwide rights to their Phase I/II gene therapeutic for adenosine deaminase deficiency-severe combined immune deficiency (ADA-SCID; also known as the bubble boy syndrome).
Deal Industry
Pharmaceuticals
Biotechnology
Gene Therapy, Cell Therapy
Large Molecule
Deal Status
Final
Deal Type
Alliance
R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?